Where each one comes from
BPC-157 (Body Protection Compound) is a synthetic peptide fragment derived from a protective protein found in gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein present in most cells and concentrated in wound fluid.
What the research focuses on
BPC-157 literature concentrates on localised repair — tendon, ligament, muscle and gut tissue models. TB-500 research skews systemic: cell migration, flexibility, and whole-body recovery models, driven by its role in actin regulation.
| BPC-157 | TB-500 | |
|---|---|---|
| Derived from | Gastric protective protein | Thymosin beta-4 |
| Research focus | Targeted tissue repair, gut | Whole-body recovery, flexibility |
| Typical format | 10mg lyophilised vial | 10mg lyophilised vial |
| Common pairing | Frequently researched together — one targeted, one systemic | |
Why they’re researched together
The pairing logic is coverage: BPC-157 models focus on a specific injured site, while TB-500 models cover generalised recovery. Together they are treated in the literature as complementary rather than redundant — which is why the combination is one of the most requested research stacks.
Handling and storage
Both ship as lyophilised (freeze-dried) powder, stable at room temperature in transit. Reconstituted with bacteriostatic water, both should be refrigerated and used within the research window. See our reconstitution guide for concentration math.